NanoVibronix Announces Presentation Of Independent Testing Results Of UroShield At ICS Annual Meeting
Portfolio Pulse from Happy Mohamed
NanoVibronix, Inc. (NASDAQ:NAOV) announced that Dr. Sandra Wilks will present the findings of her study on UroShield at the International Continence Society (ICS) 2023 Conference. The study indicates that UroShield reduces infection and catheter blockages, and has the potential to develop a healthy urinary microbiome, thus avoiding long-term use of antibiotics. The presentation at the ICS conference will increase awareness of UroShield and its benefits.

September 06, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The presentation of the UroShield study at the ICS conference could increase awareness of the product and potentially drive sales for NanoVibronix, Inc.
The presentation of positive study results at a major conference increases the visibility of the product among potential customers and healthcare professionals. This could lead to increased demand for UroShield, positively impacting NanoVibronix's sales and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100